Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;25(1):e25872.
doi: 10.1002/jia2.25872.

HIV prevention: better choice for better coverage

Linda-Gail Bekker  1 , Carey Pike  1 , Sharon L Hillier  2   3
Affiliations

HIV prevention: better choice for better coverage

Linda-Gail Bekker et al. J Int AIDS Soc. 2022 Jan.

Abstract

Introduction: Antiretroviral-based pre-exposure prophylaxis (PrEP) is today an established, effective and safe method of HIV prevention used in multiple countries worldwide by a broad range of populations at risk of HIV infection. Biomedical innovations are critical in supporting the primary prevention of HIV; however, their potential can only be maximized if end-user challenges are recognized, described and used to develop next-generation models.

Discussion: First-generation PrEP, a daily oral pill, is highly efficacious, discreet and affords users the ability to commence and conclude treatment rapidly. However, consistent daily adherence and persistence is challenging, especially among younger populations, due in part to side effects, the risk of stock-outs and a lack of pill storage options. Second-generation PrEP, longer acting agents that require less frequent dosing, could overcome such challenges. Agents that have shown efficacy in clinical trials include a monthly vaginal ring and PrEP injectables to be administered every 8 weeks, while products in development include 6 monthly injectables, oral therapy that uses monthly rather than daily pills, implants and the potential for long-acting passive immunization.

Conclusions: Second-generation PrEP agents will have the potential to offer improved adherence and less frequent reminders once they have undergone further development and the delivery systems that will best support them have been established. In order to pursue global UNAIDS targets of reducing new HIV infections to fewer than 500,000 annually by 2025, and to ensure that all people have access to prevention options that meet their specific prevention needs, both early and next-generation PrEP options are needed.

Keywords: HIV prevention; PrEP implants; injectable PrEP; long-acting PrEP; oral PrEP; pre-exposure prophylaxis.

PubMed Disclaimer

Conflict of interest statement

SLH reports receiving consulting honoraria from Merck, Gilead and ViiV and her institution receives funding from Merck. LGB reports receiving honoraria for advisory committee input to ViiV, Gilead, Merck (MSD) and Jansen. The DTHF has received grants from Gilead. CP has no competing of interests to declare.

Figures

Figure 1
Figure 1
Dosing frequency for current and emerging HIV pre‐exposure prophylaxis options.
See this image and copyright information in PMC

References

    1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;. 363(27):2587–99. - PMC - PubMed
    1. Fonner VA, Dalglish SL, Kennedy CE, Baggaley R, O'Reilly KR, Koechlin FM, et al. Effectiveness and safety of oral HIV preexposure prophylaxis for all populations. AIDS. 2016;. 30(12):1973–83. - PMC - PubMed
    1. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410. - PMC - PubMed
    1. UNAIDS . Seizing the moment: tackling entrenched inequalities to end epidemics. Global AIDS Update 2020. Geneva. Online (available): https://www.unaids.org/sites/default/files/media_asset/2020_global‐aids‐... (Accessed: 15 April 2021).
    1. Martin M, Vanichseni S, Suntharasamai P, Sangkum U, Mock PA, Chaipung B, et al. Factors associated with the uptake of and adherence to HIV pre‐exposure prophylaxis in people who have injected drugs: an observational, open‐label extension of the Bangkok Tenofovir Study. Lancet HIV. 2017;. 4(2):e59–66. - PMC - PubMed

MeSH terms